AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29771807 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 29771807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonileostomy group (n = 37)
Number of subjects: 80
Study 27048897 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (VSL#3 or E. Coli Nissle 1917)
Number of subjects: 0
Study 27048897 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 0
Study 27048897 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 26703919 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental parenteral nutrition strategy for 7 days post randomisation
Number of subjects: 100
Study 26703919 — intervention group
Group type: COMPARATOR
Intervention: Usual care with enteral nutrition
Number of subjects: 100
Study 23557411 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 μg subcutaneously every 8 h; n = 32)
Number of subjects: 62
Study 23557411 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 62
Study 23557411 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (n = 32)
Number of subjects: 62
Study 23557411 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with adenocarcinoma
Number of subjects: 62
Study 23557411 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with duct diameter >5 mm
Number of subjects: 62
Study 20450369 — intervention group
Group type: EXPERIMENTAL
Intervention: AMSA injection
Number of subjects: 50
Study 18549361 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous opioid therapy (COT)
Number of subjects: 0
Study 16389581 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational therapy approaches
Number of subjects: 227
Study 16389581 — intervention group
Group type: COMPARATOR
Intervention: Creativity-oriented ergotherapy
Number of subjects: 227
Study 14721820 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG with controlled hemodilution (Group 3)
Number of subjects: 300
Study 14721820 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG without hemodilution (Group 2)
Number of subjects: 300
Study 14721820 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiopulmonary bypass techniques (Group 1)
Number of subjects: 300
Study 10698876 — intervention group
Group type: EXPERIMENTAL
Intervention: Six week domiciliary occupational therapy
Number of subjects: 138
Study 10698876 — intervention group
Group type: COMPARATOR
Intervention: Routine follow up (Control)
Number of subjects: 138
Study 9098588 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil added to standard therapy for heart failure
Number of subjects: 2400
Study 9098588 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 2400
Study 1286418 — intervention group
Group type: EXPERIMENTAL
Intervention: 26 gauge needles
Number of subjects: 160
Study 1286418 — intervention group
Group type: COMPARATOR
Intervention: 22 gauge needles
Number of subjects: 160
Study 3954110 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine plus 0.5 ml normal saline (Group 1)
Number of subjects: 28
Study 3954110 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus 0.3 mg epinephrine (Group 2)
Number of subjects: 28
Study 3954110 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus 5 mg phenylephrine (Group 3)
Number of subjects: 28
Study 29962178 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX trial) - walking for 1 hour at 50% V̇O₂max
Number of subjects: 9
Study 29962178 — intervention group
Group type: COMPARATOR
Intervention: Control (CON trial) - resting
Number of subjects: 9
Study 29962178 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX trial)
Number of subjects: 9
Study 29962178 — intervention group
Group type: COMPARATOR
Intervention: Control (CON trial)
Number of subjects: 9
Study 27015267 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib
Number of subjects: 0
Study 27015267 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 0
Study 25554429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (20 & 40mg/70kg/h)
Number of subjects: 12
Study 25554429 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham condition)
Number of subjects: 12
Study 23958263 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for 6 months
Number of subjects: 202
Study 23958263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 20634355 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (lumbar intrathecal)
Number of subjects: 5
Study 20634355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (interspinous saline, L(3)-L(4))
Number of subjects: 5
Study 18155934 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure plus usual treatment
Number of subjects: 46
Study 18155934 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control plus usual treatment
Number of subjects: 46
Study 18155934 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients treated (pre to post-treatment)
Number of subjects: 46
Study 16177596 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g UWP/d
Number of subjects: 18
Study 16177596 — intervention group
Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 18
Study 16177596 — intervention group
Group type: COMPARATOR
Intervention: UWP and Casein placebo
Number of subjects: 18
Study 12933391 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine-prilocaine (EMLA) cream
Number of subjects: 90
Study 12933391 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine added to propofol
Number of subjects: 90
Study 12933391 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 90
Study 10376858 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 46
Study 10376858 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 46
Study 14588914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (printed manual and therapist meeting prior to discharge)
Number of subjects: 58
Study 14588914 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital treatment and discharge instructions (control group)
Number of subjects: 58
Study 14588914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 58
Study 1991923 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE antibody specific for formaldehyde-human serum albumin detected by ELISA in three subjects.
Number of subjects: 55
Study 1991923 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory challenge with formaldehyde at concentrations of up to 2 ppm.
Number of subjects: 55
Study 1991923 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum from three subjects with IgE to formaldehyde-human serum albumin by ELISA.
Number of subjects: 55
Study 1991923 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG to formaldehyde-human serum albumin detected by ELISA in three subjects and two other subjects.
Number of subjects: 55
Study 1991923 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study findings.
Number of subjects: 55
Study 1991923 — intervention group
Group type: EXPERIMENTAL
Intervention: Study conclusion.
Number of subjects: 55
Study 6109741 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine 8 mg (single dose)
Number of subjects: 5
Study 6109741 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine 8 mg (seven doses)
Number of subjects: 5
Study 6109741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg (single dose)
Number of subjects: 5
Study 6109741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg (seven doses)
Number of subjects: 5
Study 6109741 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of chlorpheniramine and cimetidine (seven doses)
Number of subjects: 5
Study 6109741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31148196 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion (T) group
Number of subjects: 15
Study 31148196 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 15
Study 29209630 — intervention group
Group type: EXPERIMENTAL
Intervention: Active participants
Number of subjects: 192
Study 29209630 — intervention group
Group type: COMPARATOR
Intervention: Inactive participants
Number of subjects: 192
Study 29209630 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of education
Number of subjects: 192
Study 29209630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of pain
Number of subjects: 192
Study 26596670 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus lenalidomide (six cycles of cyclophosphamide [300 mg/m2, days 1, 8, and 15], dexamethasone [40 mg, days 1, 8, 15, and 22], and lenalidomide [25 mg, days 1-21])
Number of subjects: 389
Study 26596670 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan (200 mg/m2) and ASCT
Number of subjects: 389
Study 26596670 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide (10 mg, days 1-21) plus prednisone (50 mg, every other day)
Number of subjects: 389
Study 26596670 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide alone
Number of subjects: 389
Study 26596670 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus lenalidomide
Number of subjects: 389
Study 24062812 — intervention group
Group type: COMPARATOR
Intervention: Personalised evaluations
Number of subjects: 615
Study 24062812 — intervention group
Group type: COMPARATOR
Intervention: Anonymous evaluations
Number of subjects: 615
Study 21931035 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐CHOP‐21
Number of subjects: 300
Study 21931035 — intervention group
Group type: COMPARATOR
Intervention: R‐CHOP‐14
Number of subjects: 300
Study 19672606 — intervention group
Group type: EXPERIMENTAL
Intervention: PCCP (Percutaneous Compression Plate)
Number of subjects: 80
Study 19672606 — intervention group
Group type: COMPARATOR
Intervention: Gamma 3 intramedullary nail
Number of subjects: 80
Study 15226056 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week aerobic and weight-training exercise plus behavior modification
Number of subjects: 0
Study 15226056 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 11407998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg
Number of subjects: 485
Study 11407998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg
Number of subjects: 485
Study 11407998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study 9215300 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mU.kg‐1.min‐1 euglycemic insulin clamp
Number of subjects: 6
Study 9215300 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mU.kg‐1.min‐1 euglycemic insulin clamp
Number of subjects: 6
Study 9215300 — intervention group
Group type: COMPARATOR
Intervention: iv 0.9% NaCl infusion after oral acipimox administration (250 mg)
Number of subjects: 6
Study 8573453 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemopreventive agents such as retinoids and tamoxifen
Number of subjects: 0
Study 2223687 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate, 1 mg (group A)
Number of subjects: 60
Study 2223687 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate, 0.5 mg (group B)
Number of subjects: 60
Study 2223687 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate, 5 mg (group C)
Number of subjects: 60
Study 2223687 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate, 2.5 mg (group D)
Number of subjects: 60
Study 573602 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein (600 units porcine pancreatic kallikrein daily for 7 weeks)
Number of subjects: 90
Study 573602 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 7 weeks)
Number of subjects: 90
Study 31680410 — intervention group
Group type: EXPERIMENTAL
Intervention: CT emulgel (4% Cinnamomum tamala extract)
Number of subjects: 13
Study 31680410 — intervention group
Group type: COMPARATOR
Intervention: Placebo (base)
Number of subjects: 13
Study 30793698 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive temperature threshold (39.5°C)
Number of subjects: 100
Study 30793698 — intervention group
Group type: COMPARATOR
Intervention: Restrictive temperature threshold (37.5°C)
Number of subjects: 100
Study 30793698 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Permissive and Restrictive)
Number of subjects: 100
Study 28645255 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin combination therapy (ACT)
Number of subjects: 8897
Study 28645255 — intervention group
Group type: COMPARATOR
Intervention: Non-ACT
Number of subjects: 8897
Study 26347106 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT/LV for 5 consecutive days per week for 18 months
Number of subjects: 1071
Study 26347106 — intervention group
Group type: COMPARATOR
Intervention: UFT/LV for 6 months (28 of 35 days)
Number of subjects: 1071
Study 24256373 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment
Number of subjects: 44
Study 24256373 — intervention group
Group type: COMPARATOR
Intervention: Control group (no isotretinoin treatment)
Number of subjects: 44
Study 21947320 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day plus modafinil 200 mg/day
Number of subjects: 46
Study 21947320 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 6 mg/day plus placebo
Number of subjects: 46
Study 20622703 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens type III
Number of subjects: 210
Study 20622703 — intervention group
Group type: COMPARATOR
Intervention: Control spectacle lenses
Number of subjects: 210
Study 17156104 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 5, 12.5, 25 or 50 mg b.i.d.
Number of subjects: 743
Study 17156104 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide 5 mg/day (titrated up to 20 mg/day)
Number of subjects: 743
Study 17156104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 743
Study 17156104 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (all doses)
Number of subjects: 743
Study 17156104 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 743
Study 17156104 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 743
Study 16044202 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay polypropylene mesh repair (group A)
Number of subjects: 41
Study 16044202 — intervention group
Group type: COMPARATOR
Intervention: Double mesh intraperitoneal repair (group B)
Number of subjects: 41
Study 12095672 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 251
Study 12095672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 9120502 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of ICAM‐1 in patients with ischaemic stroke
Number of subjects: 51
Study 9120502 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of E-selectin in patients with ischaemic stroke
Number of subjects: 51
Study 9120502 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte count in patients with ischaemic stroke
Number of subjects: 51
Study 8372418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative application of fibrin glue
Number of subjects: 100
Study 8372418 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of immunosuppressants in adults
Number of subjects: 100
Study 8372418 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of immunosuppressants in children
Number of subjects: 100
Study 8372418 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative lymph composition
Number of subjects: 100
Study 3733830 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 degrees Jewett nail-plate
Number of subjects: 98
Study 3733830 — intervention group
Group type: COMPARATOR
Intervention: 135 degrees Dynamic hip screw
Number of subjects: 98
Study 30067737 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education
Number of subjects: 184
Study 30067737 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face education (Control)
Number of subjects: 184
Study 26701155 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention promoting an active lifestyle after discharge (13 individual sessions delivered by a coach trained in motivational interviewing; began 2 months before and ended 6 months after discharge)
Number of subjects: 45
Study 26701155 — intervention group
Group type: COMPARATOR
Intervention: Regular rehabilitation including handcycle training (control group)
Number of subjects: 45
Study 24607295 — intervention group
Group type: EXPERIMENTAL
Intervention: Online asthma management program (4 online sessions)
Number of subjects: 500
Study 24607295 — intervention group
Group type: COMPARATOR
Intervention: Control asthma management program (4 online sessions)
Number of subjects: 500
Study 22176598 — intervention group
Group type: EXPERIMENTAL
Intervention: High meaningfulness and high integrative processing instruction
Number of subjects: 0
Study 22176598 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaningfulness instructions
Number of subjects: 0
Study 22176598 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing intervention
Number of subjects: 0
Study 22176598 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaningfulness and integrative processing instructions
Number of subjects: 0
Study 22176598 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported meaningfulness of the writing
Number of subjects: 0
Study 20068423 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance training (MT) for 1 year, including weekly supervised training for the first 6 months, bi-weekly supervised training for the next 6 months, and no supervised training for the last 6 months.
Number of subjects: 96
Study 20068423 — intervention group
Group type: COMPARATOR
Intervention: Control group (unsupervised training at home).
Number of subjects: 96
Study 18773755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 6600
Study 18773755 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 6600
Study 18773755 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg
Number of subjects: 6600
Study 16162814 — intervention group
Group type: EXPERIMENTAL
Intervention: Total serum homocysteine (tHcy) levels
Number of subjects: 1575
Study 16162814 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cardiovascular disease
Number of subjects: 1575
Study 16162814 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP
Number of subjects: 1575
Study 12184901 — intervention group
Group type: EXPERIMENTAL
Intervention: MIST-VR (5 sessions, 6 skills/session)
Number of subjects: 0
Study 12184901 — intervention group
Group type: COMPARATOR
Intervention: Yale Skills Course (5 sessions, 3 skills/session)
Number of subjects: 0
Study 10087737 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA)
Number of subjects: 341
Study 10087737 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA)
Number of subjects: 341
Study 10087737 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 341
Study 10087737 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (EA, SA, GA)
Number of subjects: 341
Study 7489965 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alfa2b 5 MU/m2 thrice weekly for 4 months, continued up to 12 months if ALT reduced by at least 50%
Number of subjects: 27
Study 7489965 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alfa2b
Number of subjects: 27
Study 7489965 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 27
Study 1683682 — intervention group
Group type: COMPARATOR
Intervention: H. influenzae type b polysaccharide (PRP) vaccine
Number of subjects: 248
Study 1683682 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide‐mutant diphtheria toxoid conjugate vaccine (PRP‐CRM)
Number of subjects: 248
Study 1683682 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 248
Study 6982989 — intervention group
Group type: EXPERIMENTAL
Intervention: CSFHU 10(6) units intravenously
Number of subjects: 12
Study 6982989 — intervention group
Group type: EXPERIMENTAL
Intervention: CSFHU 5 x 10(5) units intravenously
Number of subjects: 12
Study 6982989 — intervention group
Group type: EXPERIMENTAL
Intervention: CSFHU 1.3 to 1.4 x 10(7) units intravenously
Number of subjects: 12
Study 6982989 — intervention group
Group type: EXPERIMENTAL
Intervention: CSFHU 7 x 10(6) units intravenously
Number of subjects: 12
Study 31894038 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition support therapy combined with antibiotics (azithromycin plus cefuroxime sodium)
Number of subjects: 90
Study 31894038 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutritional support therapy combined with antibiotics (azithromycin plus cefuroxime sodium)
Number of subjects: 90
Study 30357266 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic hypothermia (33°C-35°C for at least 72 hours, up to 7 days if intracranial pressures were elevated)
Number of subjects: 511
Study 30357266 — intervention group
Group type: COMPARATOR
Intervention: Normothermic management (targeting 37°C)
Number of subjects: 511
Study 30357266 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic hypothermia
Number of subjects: 511
Study 30357266 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 511
Study 27052036 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin cream 12.5% applied on 80% of body surface area
Number of subjects: 10
Study 27052036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned in the abstract)
Number of subjects: 10
Study 24694876 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 60
Study 24694876 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 60
Study 22250853 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive response to MDD treatment
Number of subjects: 192
Study 22250853 — intervention group
Group type: COMPARATOR
Intervention: Initial MDD treatment (CBT, FLX, COMB, PBO)
Number of subjects: 192